Ausio Pharmaceuticals, LLC, is a clinical-stage biotechnology development company focused on the advancement of safe and effective medicines for the aging population. Ausio’s lead product is AUS-131, a first-in-class, nonsteroidal, nonhormonal estrogen receptor β (ERβ) agonist that offers a potentially safer alternative to estrogen for the treatment of menopausal symptoms and is currently in Phase 2a clinical trials. AUS-131 is also being evaluated for its potential to treat benign prostatic hyperplasia (BPH) and other indications. The company has garnered a strong patent position for AUS-131.
Ausio has rapidly developed AUS-131 as a pharmaceutical agent through a rigorous drug development process, as required by the US Food and Drug Administration. Ausio’s strategic goal is to collaborate with partners for AUS-131 in the United States and other markets worldwide.